Alkermes plc (ALKS) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Dublin, Ireland. Le PDG actuel est Richard F. Pops.
ALKS a date d'introduction en bourse 1991-07-16, 1,800 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $5.64B.
Alkermes plc is a biopharmaceutical company headquartered in Dublin, Ireland, that researches, develops, and commercializes pharmaceutical products to treat unmet medical needs across multiple therapeutic areas. The company's marketed portfolio includes ARISTADA and RISPERDAL CONSTA for schizophrenia, VIVITROL for alcohol use disorder and opioid dependence prevention, INVEGA SUSTENNA and related products for schizophrenia and schizoaffective disorder, and VUMERITY for relapsing forms of multiple sclerosis. Alkermes is also advancing pipeline candidates including LYBALVI, an oral atypical antipsychotic for schizophrenia and bipolar I disorder, and nemvaleukin alfa, an engineered immunotherapy designed to enhance anti-tumor immune responses. The company maintains significant collaboration agreements with Janssen Pharmaceuticals and operates across the United States, Ireland, and international markets.
